{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:34:05Z","timestamp":1791902045788,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012324","name":"University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004528"],"award-info":[{"award-number":["UM1TR004528"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103749","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:58:27Z","timestamp":1768395507000},"page":"103749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2282-5244","authenticated-orcid":false,"given":"Eric Edward","family":"Irons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri Ann","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Abraham","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6211","authenticated-orcid":false,"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2025.103749_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103749_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/dia.2005.7.467","article-title":"Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study","volume":"7","author":"Poon","year":"2005","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103749_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2040622315620180","article-title":"The GLP-1 receptor agonist, liraglutide, as a pharmacotherapy for obesity","volume":"7","author":"Crane","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103749_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103749_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/metabo12020183","article-title":"Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies","volume":"12","author":"Caruso","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.eclinm.2025.103749_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.eclinm.2025.103749_bib7","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103749_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-Like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103749_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djae260","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data","volume":"117","author":"Wang","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103749_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103749_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae095","article-title":"Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes","volume":"8","author":"Grandhi","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103749_bib12","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2352-3026(14)00037-4","article-title":"Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study","volume":"2","author":"Chang","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103749_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0802","article-title":"Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists","volume":"8","author":"Ashruf","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2025.103749_bib14","doi-asserted-by":"crossref","first-page":"A332","DOI":"10.1210\/jendso\/bvac150.690","article-title":"ODP242 safety of SGLT2-Inhibitors in patients with multiple myeloma and diabetes","volume":"6","author":"Shyu","year":"2022","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103749_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103749_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.eclinm.2025.103749_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2021.103847","article-title":"Assessing real-world medication data completeness","volume":"119","author":"Evans","year":"2021","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103749_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103749_bib19","first-page":"35","article-title":"Obesity and cancer risk among white and black United States veterans","volume":"15","author":"Samanic","year":"2004","journal-title":"Cancer Causes Control"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103749_bib20","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1200\/JCO.2005.11.726","article-title":"Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study","volume":"23","author":"Oh","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103749_bib21","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ejca.2008.11.004","article-title":"Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins","volume":"45","author":"S\u00f6derberg","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103749_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7861\/clinmedicine.10-5-509","article-title":"Insulin therapy and cancer risk in diabetes mellitus","volume":"10","author":"Platts","year":"2010","journal-title":"Clin Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103749_bib23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103749_bib24","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103749_bib25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41416-022-01907-2","article-title":"Anthropometric traits and risk of multiple myeloma: a pooled prospective analysis","volume":"127","author":"Bertrand","year":"2022","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103749_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41416-018-0010-4","article-title":"Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts","volume":"118","author":"Marinac","year":"2018","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103749_bib27","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","article-title":"Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC)","volume":"26","author":"Birmann","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103749_bib28","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1182\/bloodadvances.2023010822","article-title":"It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"7","author":"Choa","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103749_bib29","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103749_bib30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/oby.21894","article-title":"Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease","volume":"25","author":"Hofmann","year":"2017","journal-title":"Obesity"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103749_bib31","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","article-title":"Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells","volume":"21","author":"Caers","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103749_bib32","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-Lineage cells support growth and dissemination of multiple myeloma in bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103749_bib33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103749_bib34","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front Endocrinol"},{"issue":"494","key":"10.1016\/j.eclinm.2025.103749_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9087","article-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","volume":"11","author":"Liu","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103749_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cmet.2020.12.011","article-title":"Acetyl-CoA Synthetase 2: a critical linkage in obesity-induced tumorigenesis in myeloma","volume":"33","author":"Li","year":"2021","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103749_bib37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2014.307","article-title":"The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma","volume":"111","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2025.103749_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112864","article-title":"Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans","volume":"149","author":"Nakachi","year":"2022","journal-title":"Biomed Pharmacother"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:20:54Z","timestamp":1777634454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S2589537025006844"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103749","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103749"}}